RCAMU
ACRS icon

Rothschild & Co Asset Management US’s Aclaris Therapeutics ACRS Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-84,047
Closed -$621K – 365
2018
Q4 		$621K Buy
84,047
+35,249
+72% +$363K 0.01% 363
2018
Q3 		$709K Sell
48,798
-594
-1% -$10.2K 0.01% 360
2018
Q2 		$986K Buy
49,392
+7,446
+18% +$138K 0.01% 356
2018
Q1 		$735K Sell
41,946
-4,343
-9% -$92K 0.01% 345
2017
Q4 		$1.14M Sell
46,289
-3,494
-7% -$85.1K 0.01% 335
2017
Q3 		$1.28M Sell
49,783
-1,086
-2% -$29.1K 0.01% 319
2017
Q2 		$1.38M Sell
50,869
-2,301
-4% -$62.6K 0.02% 357
2017
Q1 		$1.59M Buy
53,170
+14,493
+37% +$418K 0.02% 340
2016
Q4 		$1.05M Buy
+38,677
New +$986K 0.01% 385

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Rothschild & Co Asset Management US's ACRS Position: Q1 2019 in Review

Rothschild & Co Asset Management US sold out of Aclaris Therapeutics (ACRS) in Q1 2019, closing a stake of 84,047 shares — an estimated $621K sold.

Rothschild & Co Asset Management US first reported a position in ACRS in Q4 2016 and held it in 9 quarters. The position peaked at $1.59M in Q1 2017. 95 funds tracked by Wall St. Rank hold ACRS as of Q1 2019.

  • Rothschild & Co Asset Management US reported no remaining Aclaris Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 84,047 Aclaris Therapeutics shares in Q1 2019, an estimated $621K.
  • Rothschild & Co Asset Management US first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 9 quarters.
  • Rothschild & Co Asset Management US's Aclaris Therapeutics position peaked at $1.59M in Q1 2017.
  • 95 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2019.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2019, filed 8 May 2019.